JPWO2019197630A5

JPWO2019197630A5 -

Info

Publication number: JPWO2019197630A5
Application number: JP2020555851A
Authority: JP
Publication date: 2022-04-14

Claims

Kit, composition, or method: where
The kit includes the following (i) and (ii) for concurrent, individual or continuous use in the treatment of Fragile X Syndrome;
The composition comprises the following (i) and (ii) for use in the treatment of Fragile X Syndrome; and
The method is a method for treating fragile X syndrome, which comprises administering the following (i) and (ii) to a patient simultaneously, individually or continuously;
(i) At least a single dose of sulindac or a pharmaceutically acceptable salt thereof ; and
(ii) At least a single dose of Compound A or a pharmaceutically acceptable salt thereof ,
Compound A is selected from the list below:
Minocycrine, Doxycycline, Robastatin, Metoformin, Epigallocatechin gallate (EGCG-green tea extract), Lithium, Tideglusib, Lamotrigine, Acamprosate, Ganaxolone, Basimglurant, mavoglurant, Methylphenidate, L-Carnitine, L-Acetylcarnitine, Zardaverine, Ibzilast, Metoprolol, Pembutrol, Fasdil, Carbamazepine, Midstaurine, Syldenafil, Tadarapyl, Gabapentine, Stilipentol, Donepegil, Tetracyclin, Cambastatin, Clumvastatin, Cambastatin Statins, losbatatin, pitavastatin, apigenin, thermisartan, medium-chain and long-chain fatty acids, indilbin, pregavalin, baclophen, arbaclophen, memantin, eschlorbinol, phenovam, rilzole, chrysabolol, S-loliplum, apremilast, syromyllast, loflumirast. , Drotavelin, Propentophylline, Caffeine, Papaverin, Trapidil, Flavoxate, Amlexano X, Pentoxyphyllin, Propanolol, Pindrol, Acebutalol, Bisoprolol, Carbegallocatechin, Labetalol, Mechipranolol, Oxprena Roll (oxprenalol), pindrol, tertatrol, timorol, topirimate, tianeptine, kercetin, diazepam, imatinib, gefitinib, selmethinib, refametinib, fushidic acid, sertraline, lorazepate, phenobarbital Luxolitinib, momelotinib, voltezomib, carfilzomib, carnosol, rilzole, luteolin, carnosic acid, resveratrol, methylphenidechin, menadione, taurine, niacin, clorazepate, diazepam, diazepam and other "azepam" drugs. Taurosporin, gaboxadol, progavid, tulrampator, ke Ketamine, decanoic acid, piracetam, pramiracetam, dexmethylphenidate, ogremirast, levetiracetam, or vigabatrin.

Use the following:
a) Sulindac or a pharmaceutically acceptable salt thereof for the manufacture of a drug for the treatment of a patient with Fragile X Syndrome, wherein said patient administers Compound A or a pharmaceutically acceptable salt thereof. Has been;
b) Compound A or a pharmaceutically acceptable salt thereof for the manufacture of a drug for the treatment of a patient with Vulnerable X Syndrome, wherein said patient receives sulindac or a pharmaceutically acceptable salt thereof. Have been administered; or
c) Sulindac or its pharmaceutically acceptable salt for the manufacture of pharmaceuticals for the treatment of Fragile X Syndrome, and Compound A or its pharmaceutically acceptable salt;
Compound A is selected from the list below:
Minocycrine, Doxycycline, Robastatin, Metoformin, Epigallocatechin gallate (EGCG-green tea extract), Lithium, Tideglusib, Lamotrigine, Acamprosate, Ganaxolone, Basimglurant, mavoglurant, Methylphenidate, L-Carnitine, L-Acetylcarnitine, Zardaverine, Ibzilast, Metoprolol, Pembutrol, Faszil, Carbamazepine, Midstaurine, Syldenafil, Tadarapyl, Gabapentine, Stilipentol, Ganaxolone, Donepegil , Fluvastatin, losvasstatin, pitabastatin, apigenin, thermisartan, medium-chain and long-chain fatty acids, indylbin, pregabalin, bacrophen, arbaclophen, memantin, eschlorbinol, phenovam, lylsole, chrysabolol, S-loliplum, apremirast, siromirast , Dipallocatechin, drotaverin, propentophilin, caffeine, papaverin, trapidil, flavoxate, amplexanox, pentoxyphyllin, propanolol, pindrol, acebutalol, bisoprolol, carbegallocatechin, labetalol Oxprenalol, Pindrol, Teltatrol, Timorol, Topiramart, Tianeptine, Kersetin, Diazepam, Imatinib, Gefitinib, Sermethinib, Refametinib, Fushidic acid, Sertralin, Lorazepate, Phenobarbital, Phenobarbital , Momelotinib, voltezomib, carfilzomib, carnosol, rilzole, luteolin, carnosic acid, resveratrol, methylphenidate, menadione, taurine, niacin, chlorazepam, diazepam, diazepam and other "azepam" drugs, chlordiazepoxide Porin, gaboxadol, progavid, tulrampator, ketamin (k) etamine), decanoic acid, piracetam, pramiracetam, dexmethylphenidate, ogremirast, levetiracetam, or vigabatrin.

Kits or compositions containing:
(i) At least a single dose of sulindac or a pharmaceutically acceptable salt thereof; and
(ii) At least a single dose of Compound A or a pharmaceutically acceptable salt thereof;
Compound A is selected from the list below:
Minocycline, Doxycycline, Methylphenidate, L-Carnitine, L-Acetylcarnitine, Zardaverine, Zardaverine , Metoprolol, Pembutrol, Fasdil, Carbamazepine, Midstaurine, Syldenafil, Tadalafil, Gabapentin, Stilpentol, Donepezil, Tetracycline, Simbatatin, Atlvastatin, Pravastatin, Fulvastatin, Losvastatin, Pitabastatin, Apigenin, Termisartane, , Eschlorbinol, Phenobarbital, Lilzole, Chrysabolol, S-Loliplum, Apremilast, Shiromirast, Loflumirast, Diazepam, Dorotaberin, Propentophylline, Papaverin, Trapidil, Flavoxate, Amplexanox (amlexano X), Pentoxyphyllin Pindrol, acebutalol, bisoprolol, carbegilol, labetarol, methiplanolol, oxprenalol, pindrol, tertatrol, timorol, topiramart, thianeptin, kelsetin, dizepam, imatinib, gefitinib, selmethinib Fushidic acid, sertraline, lorazepam, phenobarbital, valdenafil, udenafil, avanafil, luxolitinib, momerotinib, carfilzomib, carnosol, lysole, luteolin, carnosic acid, resveratrol, methylphenidate, taurine, etc. "Azepam" drugs, chlordiazepoxide, staulospolin, gaboxador (gaboxadol), progavid, tulrampator, ketamine, decanoic acid, pyrasetam, pramiracetam, dexmethylphenidate, ogremylast, levetylphenidate, levetyrasetam.

The kit or composition according to claim 3, wherein the compound A is selected from minocycline, metformin, quercetin, sertraline, topiramate, and ibudilast.

The kit, composition, method, or use according to claim 1 or 2, wherein the compound A is selected from minocycline, metformin, quercetin, sertraline, topiramate, cannabidiol, and ibudilast.

The kit, composition, method, or use for use according to any one of claims 1-5, wherein the patient presents with signs of hyperactivity, social anxiety, memory loss, and / or destructive behavior.

The kit, composition, method, or use according to any one of claims 1 to 6, wherein the patient exhibits signs of hyperactivity.

The kit, composition, method, or use according to any one of claims 1 to 7, wherein the patient presents with signs of social anxiety.

The kit, composition, method, or use according to any one of claims 1 to 8, wherein the patient presents with signs of memory loss.

The kit, composition, method, or use according to any one of claims 1 to 9, wherein the patient exhibits signs of destructive behavior.

The kit, composition, method, or use according to any one of claims 1 to 10, wherein the subject of treatment is a human.

The kit, composition, method, or use according to any one of claims 1 to 11, wherein the administration is performed by a once-daily dose.

The kit, composition, method, or use according to claim 12, wherein the once-daily dose comprises 200 mg to 400 mg of sulindac.

The kit, composition, method, or use according to any one of claims 1 to 11, wherein the administration is performed by a dose twice daily.

The kit, composition, method, or use according to claim 14, wherein the dose comprises 150 mg to 200 mg of sulindac.

The kit, composition, method, or use according to any one of claims 1 to 15, which is orally administered.

The kit, composition, method, or use according to any one of claims 1 to 15, which is administered by parenteral administration, transdermal administration, sublingual administration, rectal administration, or inhalation administration.